Discovery of 7-bromo-1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the potential epidermal growth factor receptors for tyrosine kinase inhibitors
- 18 Downloads
Small molecule tyrosine kinase inhibitors (TKIs) targeting at epidermal growth factor receptor (EGFR) in recent years have made great progress in the treatment of advanced non-small cell cancer (NSCLC). Although as the first-line treatment for sensitizing EGFR mutation-positive metastatic NSCLC, gefitinib has also behaved quite a lot of side effect and EGFR tolerance. Herein, a novel series of 7-bromo-1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives were designed and synthesized, and screened for their inhibitory activity on the EGFR high-expressing human lung adenocarcinoma cell line A549 and human large cell lung cancer cell line NCI-H460 by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide colorimetric assay. The calculated IC50 values were reported. Compound 8h demonstrated the most potent inhibitory activity (IC50 = 9.57 ± 2.20 μmol L–1 for A549 and IC50 = 13.04 ± 1.21 μmol L–1 for NCI-H460), comparable to the positive-control gefitinib (IC50 = 8.58 ± 1.65 μmol L–1 for A549 and IC50 = 18.66 ± 5.01 μmol L–1 for NCI-H460). Conclusively, 7-bromo- 1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as the EGFR–TKIs were discovered, and could be used as potential leading compounds for further research.
KeywordsEGFR Inhibitors Heterocycle Synthesis Anticancer activities
This work was supported by the National Science Foundation of China (NSFC) for the grant No. 21342006 and the Program for Innovative Research Team of the Ministry of Education of China for the grant No. IRT_14R36. We thank Molegro ApS for kindly providing a free evaluation copy of their software package and Schrödinger, LLC for allowing the use of PyMOL Molecular Graphics System.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with animals, performed by any of the authors. Informed consent was obtained from all individual participants included in the study.
- Cagniant P, Cagniant D (1966) Contibution àl’étude des hétérocycles soufrés condensés.Dérivés du dihydro-5,6 4H thiéno-[2,3-b]-thiopyranne, du dihydro-5,6 7H thiéno [3,2-b]-thiopyranne et de la tétrahydro-5,6,7,8 thiéno[3,2-b]-thiépinne. Bull Soc Chim Fr 7:2172–2179Google Scholar
- Coumar MS, Chu CY, Lin CW, Shiao HY, Ho YL, Reddy R, Lin WH, Chen CH, Peng YH, Leou JS, Lien TW, Huang CT, Fang MY, Wu SH, Wu JS, Chittimalla SK, Song JS, Hsu JT, Wu SY, Liao CC, Chao YS, Hsieh HP (2010) Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem 53(13):4980–4988CrossRefGoogle Scholar
- Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874CrossRefGoogle Scholar
- Guo ZR (2008) Strategy of molecular drug design: pharmacophore and scaffold hopping. Chin J Med Chem 18:147–157Google Scholar
- Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K (2015) Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 4:156–164Google Scholar
- Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 361:947–957CrossRefGoogle Scholar
- National Comprehensive Cancer Network. Non-small Cell Lung Cancer (Version 2, 2016). Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 2015-12-01
- Ponticello GS, Freedman MB, Habecker CN, Habecker CN, Holloway MK, Amato JS, Conn RS, Baldwin JJ (1988) Utilization of α, β-unsaturated acids as Michael acceptors for the synthesis of thieno[2,3-b]thiopyrans. J Org Chem 1988 53:9–13Google Scholar
- Sun B, Zhang J, Yin XE, Xu Y, Zhang FR, Huang YS, Wang JH, Wang GQ, Hu C (2016) Synthesis, characterization and biological activity of thieno[2,3-d]pyrimidine derivatives as the epidermal growth factor receptor inhibitors. Lat Am J Pharm 35:570–577Google Scholar
- Sun R, Song J, Zhao H, Yan CL, Zhang AJ, Koirala D, Li DW, Hu C (2011) Synthesis and anti-tumor activity of 1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives. J Chin Pharm Sci 20:26–34Google Scholar
- Wissner A, Mansour TS (2008) The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm 2008 341(8):465–477Google Scholar
- Wood ER, Shewchuk LM, Ellis B, Brignola P, Brashear RL, Caferro TR, Dickerson SH, Dickson HD, Donaldson KH, Gaul M, Griffin RJ, Hassell AM, Keith B, Mullin R, Petrov KG, Reno MJ, Rusnak DW, Tadepalli SM, Ulrich JC, Wagner CD, Vanderwall DE, Waterson AG, Williams JD, White WL, Uehling DE (2008) 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases. Proc Natl Acad Sci USA 105(8):2773–2778CrossRefGoogle Scholar
- Wu CH, Coumar MS, Chu CY, Lin WH, Chen YR, Chen CT, Shiao HY, Rafi S, Wang SY, Hsu H, Chen CH, Chang CY, Chang TY, Lien TW, Fang MY, Yeh KC, Chen CP, Yeh TK, Hsieh SH, Hsu JT, Liao CC, Chao YS, Hsieh HP (2010) Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency. J Med Chem 53(20):7316–7326CrossRefGoogle Scholar
- Zhao Y, Wu XR, Yin JG, Wang JJ (2002) Synthesis of isochromano[4,3-C]pyrazole substituted with biheterocycle at 3-position. J Yantai Univ Nat Sci Eng Ed 15:113–117Google Scholar